Machiraju et al. observed that in metastatic melanoma, decreased PFS under anti-PD-1 treatment is associated with a higher amount of LAG3+ (p = 0.07) and TIM-3+ (p = 0.019) TILs [35]. Here, PDCD1 is linked to metastatic melanoma.